Epigral zoomed 11.72% to Rs 1,642.65 after the company's consolidated net profit stood at Rs 86 crore in Q1 FY25, steeply higher than Rs 32 crore posted in corresponding quarer last year.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.